🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Thanks to the students who came out to the meeting and voted. Congratulations to our new ISPE Student Council co-chair Caroline Walsh !!

Thank you, @amelia_tcd, for a job well done these past two years!

Past, present, and future ISPE Student Council chairs! The council is in great hands - congrats Caroline Walsh on keeping the Irish representation going!🇮🇪 #ICPEPrague

Excited to work with Lindsay W In the coming year. Have big shoes (not literally 😂) to fill from @amelia_tcd. Keep an eye on ISPE Student Council for news!

It's a wrap! Thanks for joining us at another successful @ICPE #ICPEPrague #ICPE2018. Stay tuned for news of our next journey to #ISPEMY Rome April 6-9, 2019!!

First day at #myispe19 Rome - Program planning for ICPE Philadelphia! Looking forward to the welcome reception this evening!

Like 3 different but complementary gelato flavours ISPE Student Council #MYISPE19 Rome!

Annalisa Lezzi from AbbVie at #ICPEMY19 asking the audience: On use of biosimilars, are we lacking knowledge on what questions to ask? #epi #rxepi @ICPE

Join the conversation on biologics and biosimilars #myispe19 @ICPE #RxEpi. How can we improve data capture to identify which product/batch administered to patients? Role for pharmacists.

Trend towards disease registries vs drug registries. Novel studies with patient experience registries. Important to engage patients in research to report adverse events and quality of life outcomes. Overall goal- generate meaningful data. #myispe19 @ICPE #RxEpi

Next presentation by Ippazio Cosimo Antonazzo focuses on an additive model approach to test drug-drug interaction between oral antidiabetics and statins on myopathy in the FDA Adverse Event Reporting System. #myispe19 #RxEpi #EpiTwitter @ICPE

Interesting to hear about the Danish healthcare system wrt #biosimilar use in Rheumatology....#myispe19 #epitwitter

Bente Glintborg providing the clinical rheumatology experience with originator and biosimilar interchangeability using the Danish DANBIO disease registry. #myispe19 #RxEpi #EpiTwitter @ICPE

Patient-related factors, not drug itself, can affect the reason for switching from originator to biosimilar and the outcome/how the drug performs. #myispe19 #RxEpi #EpiTwitter @ICPE

The debate continues: how does non-medical/policy-driven switch between biologics to biosimilars impact clinical decisions/care and patient experience? #myispe19 #RxEpi #EpiTwitter @ICPE

Transparency and reproducibility is needed for use of emerging data sources for evidence generation! #myispe19 #RxEpi #EpiTwitter @ICPE

Discussion on implications of biologic and biosimilar batch-to-batch variability for comparative effectiveness studies #myispe19 #RxEpi #epitwitter